Latest revenue
$25.0K
as of 2026-03-31
Latest net income
$-2.8M
as of 2026-03-31
Net margin
-11000.0%
as of 2026-03-31
ActaClear Score
Computed from 5 years of SEC fundamentals + latest market data, ranked within Pharmaceutical Preparations (528 peers). 10 = best in industry, 5 = median, 0 = worst. Refreshed Jun 7, 2026.
Community sentiment
Where do you think ALLR is heading?
Price · 5Y
Market data
Price feed temporarily unavailable for ALLR.
5-year trend
What this company does
Item 1. Business. Overview We are a clinical-stage, precision medicine pharmaceutical company focused on developing novel anti-cancer therapeutics for patients with high unmet medical need. We were founded on the innovation of our novel Drug Response Predictor (DRP®) platform. The DRP® technology is designed to define the gene expression signatures in cancer cells that predict the cancer cell’s sensitivity to a specific cancer therapeutic. Once defined, the DRP® gene expression signature can then be assessed in cancer tissue biopsies from patients to identify those cancers that share this signature of drug sensitivity, and by extension, to identify those patients who may then be most likely…
AI summary unavailable — showing raw filing excerpt
Generated from ALLR's filing dated 2026-03-30
Key risks
Item 1A. Risk Factors. An investment in our shares of common stock involves a high degree of risk. Before making an investment decision, you should give careful consideration to the following risk factors, in addition to the other information included in this Annual Report, including our financial statements and related notes, before deciding whether to invest in shares of our common stock. The occurrence of any of the adverse developments described in the following risk factors could materially and adversely harm our business, financial condition, results of operations or prospects. In that case, the trading price of our shares of common stock could decline, and you may lose all or part of…
AI summary unavailable — showing raw filing excerpt
Generated from ALLR's filing dated 2026-03-30
Profitability
Operating margin
-3939.1%
Net margin
-3509.7%
Return on equity
-114.3%
44.9%Return on assets
-61.5%
43.2%Leverage
Debt / equity
0.86×
6.5%Long-term debt / equity
-9.58×
Debt / assets
46.2%
3.5%Earnings tracker
| Quarter | Revenue | YoY | Net income | YoY | Net margin |
|---|---|---|---|---|---|
Q1 2026 2026-03-31 | $25.0K | — | $-2.8M | -0.7% | -11000.0% |
Q4 2025 2025-12-31 | — | — | $-3.4M | +54.7% | — |
Q3 2025 2025-09-30 | — | — | $-2.8M | +75.8% | — |
Q2 2025 2025-06-30 | — | — | $-2.3M | -42.4% | — |
Q1 2025 2025-03-31 | $0 | — | $-2.7M | +28.9% | — |
Q4 2024 2024-12-31 | — | — | $-7.5M | — | — |
Q3 2024 2024-09-30 | — | — | $-11.6M | -160.6% | — |
Q2 2024 2024-06-30 | — | — | $-1.6M | +31.6% | — |
Year-over-year change vs the same fiscal quarter one year prior. Revenue + net income sourced from SEC 10-Q / 10-K filings — no analyst-consensus dependency.
Industry trend
Pharmaceutical Preparations · SIC 2834
Your notes
Keep private notes on ALLR — thesis, target price, catalysts to watch.
Visible only to you. Never shared. Never used to train AI.
Insider activity
Insider buying
$0
Insider selling
$0
Net activity
+$0
Distinct insiders
0
Open-market trades over the last 365 days.
Recent transactions
| Date | Insider | Type | Shares | Price | Value |
|---|
Source: SEC Form 4 filings. Officers, directors, and 10%+ owners must disclose share transactions within two business days. RSU grants and tax-withholding rows are excluded by default — compensation activity is not a trading signal.
Who owns ALLR
Institutional value
$302.6K
Total shares held
277.6K
Distinct holders
6
-9 vs prior
As of
2026-03-31
Prior: 2025-12-31
Filers with $100M+ AUM disclose holdings 45 days after quarter end.
Top institutional holders
| # | Manager | Shares | Value | QoQ change | Action |
|---|---|---|---|---|---|
| 1 | VANGUARD CAPITAL MANAGEMENT LLC | 171.8K | $187.3K | — | New |
| 2 | VANGUARD FIDUCIARY TRUST CO | 74.9K | $81.7K | — | New |
| 3 | UBS Group AG | 23.2K | $25.2K | -3.4K (-12.7%) | Trimmed |
| 4 | CITIGROUP INC | 7.8K | $8.5K | — | New |
| 5 | DANSKE BANK A/S | 1 | $1 | +0 (+0.0%) | No change |
| 6 | Caitong International Asset Management Co., Ltd | 1 | $1 | — | New |
Source: SEC Form 13F-HR. Positions aggregated across sub-managers within each firm. Options (puts/calls) excluded — common stock only.
Top questions investors are asking
Coming once ALLR's latest filing finishes processing.
Sign in to vote. Votes use 7-day half-life decay.
Sign in to tap. 7-day half-life decay.